EGHT shares have plunged 23.4% in the trailing 12-month period, outperforming the Zacks Computer & Technology sector’s return of 27.1% and the Zacks Internet Software industry’s appreciation of 31.5%.
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the ...